Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MELADERM-trial: Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer: a Pivotal Phase 2, Double-blind, Randomized, Placebo-controlled Trial

NCT03716583 is registered in ClinicalTrials.gov with Dennis Bregner Zetner as lead sponsor.

NCT NCT03716583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03716583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MELADERM-trial: Melatonin Cream Against Acute Radiation Dermatitis in Patients With Early Breast Cancer: a Pivotal Phase 2, Double-blind, Randomized, Placebo-controlled Trial
Lead sponsor
Dennis Bregner Zetner
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2019
Completion date
January 31, 2021
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, radiation dermatitis, radiation dermatitis acute